Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors

Inclusion Criteria: * Histologically confirmed solid tumors * Tumor progression after receiving standard/approved chemotherapy and for whom no available treatment provides clinical benefit * One or more metastatic tumors measurable on a CT scan or MRI per RECIST criteria * ECOG performance 0-1 * Life expectancy of at least 3 months * Age \>/= 18 years * A negative pregnancy test (if female of child-bearing potential) * Acceptable liver function: * Bilirubin \</= 1.5 times the Upper Limit of Normal (ULN) * AST (SGOT), ALT (SGPT) and Alkaline phosphatase \</= 2.5 times ULN (if liver metastases are present, then \</= 5 times ULN is allowed) * Acceptable renal function: * Serum creatinine within normal limits, OR calculated creatinine clearance \>/= 60 mL/min/1.73m2 for patients with creatinine levels above institutional normal * Acceptable hematologic status: * Granulocyte count \>/= 1500 cells/mm3 * Platelet count \>/= 100,000 (plt/mm3) * Hemoglobin \>/= 9.0 g/dL * Urinalysis: no clinically significant abnormalities * Acceptable coagulation status: * PT within normal limits * aPTT within normal limits * Completed any chemotherapy, major surgery, or irradiation at least four weeks before enrollment in this study (six weeks for mitomycin-C or nitrosoureas, and two weeks for "targeted" therapies such as kinase inhibitors). Patient must have recovered from all toxicities incurred as a result of previous therapy. * QT intervals of QTC \</= 450 msec for men and \</= 470 msec for women (as measured by Hodges equation) * Left ventricular ejection fraction \>/= 50% by 2D Echocardiogram (or \> institutional lower limits of normal) Exclusion Criteria: * NYHA Class III or IV, cardiac disease, myocardial infarction within the past six months, unstable arrhythmia, or evidence of ischemia on ECG * Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy * Pregnant or nursing women * Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry (six weeks for mitomycin-C or nitrosoureas and two weeks for targeted therapies such as kinase inhibitors). * Unwillingness or inability to comply with protocol procedures * Known current infection with HIV, hepatitis B or hepatitis C * Currently receiving any other investigational agent * Currently receiving medications metabolized by the cytochrome P450 3A4 enzyme pathway * Presence of clinically apparent central nervous system metastases or carcinomatous meningitis. Patients with brain metastases which are well controlled (patients not taking dexamethasone or anti-seizure medication \>/= three months after treatment) may be enrolled. * Any other severe concurrent disease, which in the judgement of the investigator would make the patient inappropriate for the study * Diagnosis of hypertension * Previously enrolled in this trial